Geneva, May 4 -- International Clinical Trials Registry received information related to the study (ChiCTR2600123098) titled 'First-in-Human Assessment of a 64Cu-Labeled Novel HER2-Targeting minibinder for PET/CT Imaging in Recurrent/Metastatic HER2-Positive Breast and Gastric Cancers: Safety, Biodistribution, and Dosimetry' on April 21.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University
Condition:
HER2-positive recurrent/metastatic breast cancer and gastric cancer
Intervention:
Native conformation:64Cu-Labeled Novel HER2-Targeted minibinder (Native Conformation)
ABD1 conformation:64Cu-Labeled Novel HER2-Targeted minibinder (ABD1 Conformation)
Recru...